drugset
drugset / Trial / NCT05715398

BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer

NCT05715398 ↗

Phase 1/2 Unknown 90 enrolled Shanghai Gopherwood Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase Ⅰ/Ⅱa, multi-center, open-label study, aiming to evaluate the safety, tolerability, pharmacokinetic (PK), and efficacy of BR790 in combination with anlotinib in adult participants with advanced NSCLC.

Timeline

Start
2023-02
Primary completion
2024-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BR790 Unknown — Oral
Background Catequentinib Small molecule — Oral

Indications

non-small cell lung carcinoma